Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trialResearch in context

MLA

Masato Takahashi, et al. “Eribulin versus S-1 as First or Second-Line Chemotherapy to Assess Health-Related Quality of Life and Overall Survival in HER2-Negative Metastatic Breast Cancer (RESQ Study): A Non-Inferiority, Randomised, Controlled, Open-Label, Phase 3 TrialResearch in Context.” EClinicalMedicine, vol. 74, no. 102715-, Aug. 2024. EBSCOhost, https://doi.org/10.1016/j.eclinm.2024.102715.

APA

Masato Takahashi, Yuichiro Kikawa, Kosuke Kashiwabara, Naruto Taira, Tsuguo Iwatani, Kojiro Shimozuma, Shoichiro Ohtani, Tetsuhiro Yoshinami, Junichiro Watanabe, Masahiro Kashiwaba, Ken-ichi Watanabe, Masahiro Kitada, Koichi Sakaguchi, Yuko Tanabe, Tomohiko Aihara, & Hirofumi Mukai. (2024). Eribulin versus S-1 as first or second-line chemotherapy to assess health-related quality of life and overall survival in HER2-negative metastatic breast cancer (RESQ study): a non-inferiority, randomised, controlled, open-label, phase 3 trialResearch in context. EClinicalMedicine, 74(102715-). https://doi.org/10.1016/j.eclinm.2024.102715

Chicago

Masato Takahashi, Yuichiro Kikawa, Kosuke Kashiwabara, Naruto Taira, Tsuguo Iwatani, Kojiro Shimozuma, Shoichiro Ohtani, et al. 2024. “Eribulin versus S-1 as First or Second-Line Chemotherapy to Assess Health-Related Quality of Life and Overall Survival in HER2-Negative Metastatic Breast Cancer (RESQ Study): A Non-Inferiority, Randomised, Controlled, Open-Label, Phase 3 TrialResearch in Context.” EClinicalMedicine 74 (102715-). doi:10.1016/j.eclinm.2024.102715.